

# EuroSIDA Newsletter

February 2017



## ANNOUNCEMENTS

### Dear EuroSIDA Study Investigators,

Many greetings to all of you from the EuroSIDA coordinating office. We wish you a great 2017 and we thank you again for your continued excellent work and important contributions to the EuroSIDA study.

## Study updates

### Dataset 44

Dataset 44 data collection has finished with a very impressive and satisfying outcome. More than 13,500 follow-up forms were completed which is the highest number of FU-forms completed in EuroSIDA history. Data was reported by 92 sites out of 100 currently active sites across Europe, Israel and Argentina. We have received positive feedback regarding the recent structural changes in EuroSIDA and the impact on the workload of the sites and the coordinating centre is beginning to show.

### Enrolment in Cohort 10

Enrolment in the HCV cohort ended on 31 December 2016. More than 4,000 coinfecting patients were included and will be part of prospective follow-up together with more than 2,000 coinfecting patients enrolled in earlier cohorts. This large number of HIV/HCV coinfecting patients ensures EuroSIDA a strong base to investigate treatment benefits and adverse effects of the new HCV DAA treatment.

We send a huge thanks to all centres that have contributed with data towards this cohort!

## EuroSIDA scientific interest groups

As you are probably aware, we have launched 7 EuroSIDA **Scientific Interest Groups**. Two teleconference for each SIG have been planned and the second round of TC's is currently proceeding. We invite all of you to participate in the SIGs to help shape a future research agenda that will improve care and outcomes for PLHIV.

Please contact the EuroSIDA coordinating centre if you have not yet joined a SIG and you wish to participate and contribute with new research proposals. Please find the SIG's and upcoming TC's [HERE](#).

## PUBLICATIONS

We wish to commend EuroSIDA investigators, as a noteworthy

### **Deadlines:**

**Please continue to complete HCV Treatment and Adverse Event forms, INSTI HSR form, and CoDe form when relevant. The next dataset (45) is planned for 1 June 2017**

### HepHIV Conference 2017, Malta

EuroSIDA was represented at the conference with two poster presentations. Please read them [HERE](#)

*"Variation in ART-coverage and virological suppression among HIV key population"s*, presented by Kamilla Laut on behalf of EuroSIDA.

*"Regional differences across Europe in advanced fibrosis and cirrhosis among HIV/HCV co-infected persons between 2010-2015"*, presented by Sarah Amele on behalf of EuroSIDA.

### Contracts and reimbursement

The coordinating centre is in the process of developing new contracts which will be sent to all sites for review and signatures in the near future. Former EuroCoord partner sites will be reimbursed for their EuroSIDA activities in DS42-DS43 as soon as the new contracts have been fully executed. The next reimbursement covering DS44 activities is planned for October 2017. We thank all for your understanding and patience.

### Plasma samples

Plasma sample should still if possible be collected twice a year for all patients participating in EuroSIDA. This

milestone has been reached and exceeded. EuroSIDA has, through own publications and in collaboration with other cohorts, published more than 250 peer reviewed articles! Currently the count has reached 256 with two more in press!

Total number of publications in 2017: 4

Publications since last newsletter November 2016: 5

**One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America.** D.N. Podlekareva, A. Schultze, A. Panteleev, A.M. Skrahina, J.M. Miro, A. Rakhmanova†, H. Furrer, R.F. Miller, A.M. W. Efsen, M.H. Losso, J. Toibaro, A. Vassilenko, E. Girardi, J.D. Lundgren, A. Mocroft, F.A. Post, O. Kirk, on behalf of the TB:HIV study group in EuroCoord. AIDS. 2017;31(3):375-384.

**Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study.** Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Ann Intern Med. 2017 Jan 3;166(1):9-17.

**Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.** Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. HIV Med. 2017 Jan;18(1):33-44.

**Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death.** M Casadellà; A Cozzi-Lepri; A Phillips; M Noguera-Julian; M Bickel; D Sedlacek; K Zilmer; B Clotet; JD Lundgren; R Paredes, on behalf of EuroSIDA in EuroCoord. PLoS One. 2017 Jan 27;12(1):e0166613.

**Predictive value of prostate specific antigen in a European HIV-positive cohort: Does one size fit all?** Leah Shepherd, Álvaro H. Borges, Lene Ravn, Richard Harvey, Mark Bower, Andrew Grulich, Michael Silverberg, Gitte Kronborg, Massimo Galli, Ole Kirk, Jens Lundgren, Amanda Mocroft on behalf of EuroSIDA in EuroCoord. Antivir Ther. 2016;21(6):529-534.

#### **Press article on recent EuroSIDA findings**

Press review based on the EuroSIDA [Publication](#) which finds that new cancer rates climb with age in HIV patients, but age impact differs by cancer type. Read the press article in HIV Treatment Alerts [HERE](#). (Article 3, page 9)

All EuroSIDA publications may be found [HERE](#)

can occur together with any scheduled visit to the clinic.

#### **EuroSIDA study documents**

Please remember that you can find relevant study documents [HERE](#).

#### **Change in staff and REDCap login**

Please remember to update the EuroSIDA coordinating centre if there are changes to staff. This allows information, newsletters etc. to be sent to the right person and also allows us to keep the study group updated and thus award co-authorships to the right people. Furthermore, if staff no longer works at your site, we need to remove their REDCap access.

Please also make sure that you use your own unique REDCap login information. If you enter REDCap data using another person's REDCap login, please contact the EuroSIDA coordinating centre and we will send you your own login information.

#### **Contact**

Please always feel free to contact the EuroSIDA coordinating centre at [eurosidea.rigshospitalet@regionh.dk](mailto:eurosidea.rigshospitalet@regionh.dk) No question is too small or too big, we are happy to assist in all matters!



Thank you for a continuous rewarding and  
successful collaboration!

---

EuroSIDA Coordinating Centre. Rigshospitalet, CHIP, Department of Infectious Diseases, Section 2100, Finsencentret. Blegdamsvej 9, DK-  
2100 Copenhagen Ø, Denmark.

Tel: +45 35 45 57 57. Fax: +45 35 45 57 58. E-mail: [EuroSIDA.rigshospitalet@regionh.dk](mailto:EuroSIDA.rigshospitalet@regionh.dk)

Web: [www.regionh.dk](http://www.regionh.dk) [www.chip.dk](http://www.chip.dk)